{"analyses":[{"ciLowerLimit":"85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"436","groupDescription":"Estimated median survival time","groupIds":["OG000"],"nonInferiorityType":"OTHER","paramType":"Median Disease Free Survival Time","paramValue":"172"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85","upperLimit":"436","value":"172"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Disease Free Survival measured by median survival time in days","dispersionType":"95% Confidence Interval","groups":[{"description":"Intravenous busulfan (Busulfan®) in combination with fludarabine\n\nBusulfan: Daily intravenous dosing to target AVC\n\nFludarabine: Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.\n\nCampath: All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).\n\nStem Cell Transplant: Infusion of bone marrow and donors(related/ unrelated).","id":"OG000","title":"Busulfan and Fludarabine"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"5 years","title":"Disease Free Survival","type":"SECONDARY","unitOfMeasure":"days"}